CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety
Isabella Piassi Godói1,2, Livia Lovato Pires Lemos2, Vânia Eloisa de Araújo3
1Programa de Pós-graduação em Medicamentos e Assistência Farmacêutica, sala 1023, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais, CEP 31270-901, Brazil.
Introduction:
Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia®) was the first vaccine to gain regulatory approval to try and address this problem.
Aim:
Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine.
Method:
Meta-analysis and systematic review.
Results:
The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events.
Conclusion:
CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.
